Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Discovered and characterized at The University of North Carolina at Chapel Hill, the compound showed potent PDE4D inhibition ...

Discover how immune checkpoint inhibitors, a revolutionary cancer therapy, increase psoriasis risk. Essential insights for ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Could ultra-processed foods be fueling your psoriasis? A new study suggests a link between high consumption of these foods ...

Psoriasis severity and systemic inflammation linked to cardiovascular disease: insights for better patient care.

Nov. 12, 2024 — Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other ...

Mindera Health's Mind.Px™, the first and only predictive test of its kind, uses advanced gene expression analysis to help ...